$TEVA Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.86 up 10.26% YoY
• Reported revenue of $4.39B down -1.90% YoY
• Teva raised 2026 revenue guidance to $16.7B and non-GAAP diluted EPS guidance to $1.92; free cash flow guidance is $2.1B, with higher outlooks for AUSTEDO, AJOVY and UZEDY.